{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:46:37Z","timestamp":1791229597562,"version":"4.1.0"},"reference-count":107,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III (ISCIII) and FEDER","award":["PI21\/00983"],"award-info":[{"award-number":["PI21\/00983"]}]},{"name":"Instituto de Salud Carlos III (ISCIII) and FEDER","award":["SA118P20"],"award-info":[{"award-number":["SA118P20"]}]},{"name":"Instituto de Salud Carlos III (ISCIII) and FEDER","award":["AP176752021"],"award-info":[{"award-number":["AP176752021"]}]},{"name":"Instituto de Salud Carlos III (ISCIII) and FEDER","award":["RD12\/0036\/0069"],"award-info":[{"award-number":["RD12\/0036\/0069"]}]},{"name":"Instituto de Salud Carlos III (ISCIII) and FEDER","award":["CIBERONC CB16\/12\/00233"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00233"]}]},{"name":"Instituto de Salud Carlos III (ISCIII) and FEDER","award":["JCYL-EDU\/1868\/2022"],"award-info":[{"award-number":["JCYL-EDU\/1868\/2022"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n-Junta de Castilla y Le\u00f3n","award":["PI21\/00983"],"award-info":[{"award-number":["PI21\/00983"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n-Junta de Castilla y Le\u00f3n","award":["SA118P20"],"award-info":[{"award-number":["SA118P20"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n-Junta de Castilla y Le\u00f3n","award":["AP176752021"],"award-info":[{"award-number":["AP176752021"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n-Junta de Castilla y Le\u00f3n","award":["RD12\/0036\/0069"],"award-info":[{"award-number":["RD12\/0036\/0069"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n-Junta de Castilla y Le\u00f3n","award":["CIBERONC CB16\/12\/00233"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00233"]}]},{"name":"Consejer\u00eda de Educaci\u00f3n-Junta de Castilla y Le\u00f3n","award":["JCYL-EDU\/1868\/2022"],"award-info":[{"award-number":["JCYL-EDU\/1868\/2022"]}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","award":["PI21\/00983"],"award-info":[{"award-number":["PI21\/00983"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","award":["SA118P20"],"award-info":[{"award-number":["SA118P20"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","award":["AP176752021"],"award-info":[{"award-number":["AP176752021"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","award":["RD12\/0036\/0069"],"award-info":[{"award-number":["RD12\/0036\/0069"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","award":["CIBERONC CB16\/12\/00233"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00233"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","award":["JCYL-EDU\/1868\/2022"],"award-info":[{"award-number":["JCYL-EDU\/1868\/2022"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en C\u00e1ncer (RTICC)","award":["PI21\/00983"],"award-info":[{"award-number":["PI21\/00983"]}]},{"name":"Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en C\u00e1ncer (RTICC)","award":["SA118P20"],"award-info":[{"award-number":["SA118P20"]}]},{"name":"Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en C\u00e1ncer (RTICC)","award":["AP176752021"],"award-info":[{"award-number":["AP176752021"]}]},{"name":"Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en C\u00e1ncer (RTICC)","award":["RD12\/0036\/0069"],"award-info":[{"award-number":["RD12\/0036\/0069"]}]},{"name":"Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en C\u00e1ncer (RTICC)","award":["CIBERONC CB16\/12\/00233"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00233"]}]},{"name":"Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en C\u00e1ncer (RTICC)","award":["JCYL-EDU\/1868\/2022"],"award-info":[{"award-number":["JCYL-EDU\/1868\/2022"]}]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","award":["PI21\/00983"],"award-info":[{"award-number":["PI21\/00983"]}]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","award":["SA118P20"],"award-info":[{"award-number":["SA118P20"]}]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","award":["AP176752021"],"award-info":[{"award-number":["AP176752021"]}]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","award":["RD12\/0036\/0069"],"award-info":[{"award-number":["RD12\/0036\/0069"]}]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","award":["CIBERONC CB16\/12\/00233"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00233"]}]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","award":["JCYL-EDU\/1868\/2022"],"award-info":[{"award-number":["JCYL-EDU\/1868\/2022"]}]},{"name":"FEHH (\u201cFundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia\u201d; Beca de Investigaci\u00f3n FEHH 2022)","award":["PI21\/00983"],"award-info":[{"award-number":["PI21\/00983"]}]},{"name":"FEHH (\u201cFundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia\u201d; Beca de Investigaci\u00f3n FEHH 2022)","award":["SA118P20"],"award-info":[{"award-number":["SA118P20"]}]},{"name":"FEHH (\u201cFundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia\u201d; Beca de Investigaci\u00f3n FEHH 2022)","award":["AP176752021"],"award-info":[{"award-number":["AP176752021"]}]},{"name":"FEHH (\u201cFundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia\u201d; Beca de Investigaci\u00f3n FEHH 2022)","award":["RD12\/0036\/0069"],"award-info":[{"award-number":["RD12\/0036\/0069"]}]},{"name":"FEHH (\u201cFundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia\u201d; Beca de Investigaci\u00f3n FEHH 2022)","award":["CIBERONC CB16\/12\/00233"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00233"]}]},{"name":"FEHH (\u201cFundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia\u201d; Beca de Investigaci\u00f3n FEHH 2022)","award":["JCYL-EDU\/1868\/2022"],"award-info":[{"award-number":["JCYL-EDU\/1868\/2022"]}]},{"name":"\u201cAyuda predoctoral de la Junta de Castilla y Le\u00f3n\u201d by the Fondo Social Europeo Plus (FSE+ )","award":["PI21\/00983"],"award-info":[{"award-number":["PI21\/00983"]}]},{"name":"\u201cAyuda predoctoral de la Junta de Castilla y Le\u00f3n\u201d by the Fondo Social Europeo Plus (FSE+ )","award":["SA118P20"],"award-info":[{"award-number":["SA118P20"]}]},{"name":"\u201cAyuda predoctoral de la Junta de Castilla y Le\u00f3n\u201d by the Fondo Social Europeo Plus (FSE+ )","award":["AP176752021"],"award-info":[{"award-number":["AP176752021"]}]},{"name":"\u201cAyuda predoctoral de la Junta de Castilla y Le\u00f3n\u201d by the Fondo Social Europeo Plus (FSE+ )","award":["RD12\/0036\/0069"],"award-info":[{"award-number":["RD12\/0036\/0069"]}]},{"name":"\u201cAyuda predoctoral de la Junta de Castilla y Le\u00f3n\u201d by the Fondo Social Europeo Plus (FSE+ )","award":["CIBERONC CB16\/12\/00233"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00233"]}]},{"name":"\u201cAyuda predoctoral de la Junta de Castilla y Le\u00f3n\u201d by the Fondo Social Europeo Plus (FSE+ )","award":["JCYL-EDU\/1868\/2022"],"award-info":[{"award-number":["JCYL-EDU\/1868\/2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is a disease of the elderly, but chronological age does not accurately discriminate frailty status at the inter-individual level. Frailty describes a person\u2019s overall resilience. Since CLL is a stressful situation, it is relevant to assess the patient\u00b4s degree of frailty, especially before starting antineoplastic treatment. We are in the era of targeted therapies, which have helped to control the disease more effectively and avoid the toxicity of chemo (immuno) therapy. However, these drugs are not free of side effects and other aspects arise that should not be neglected, such as interactions, previous comorbidities, or adherence to treatment, since most of these medications are taken continuously. The challenge we face is to balance the risk of toxicity and efficacy in a personalized way and without forgetting that the most frequent cause of death in CLL is related to the disease. For this purpose, comprehensive geriatric assessment (GA) provides us with the opportunity to evaluate multiple domains that may affect tolerance to treatment and that could be improved with appropriate interventions. In this review, we will analyze the state of the art of GA in CLL through the five Ws.<\/jats:p>","DOI":"10.3390\/cancers15174391","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T02:43:20Z","timestamp":1693795400000},"page":"4391","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Five \u201cWs\u201d of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6329-1704","authenticated-orcid":false,"given":"Isabel","family":"Gonz\u00e1lez-Gasc\u00f3n-y-Mar\u00edn","sequence":"first","affiliation":[{"name":"Department of Hematology, University Hospital Infanta Leonor, 28031 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Ballesteros-Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Hematology, University General Hospital Gregorio Mara\u00f1\u00f3n, 28009 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mart\u00ednez-Flores","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, University Hospital Infanta Leonor, 28031 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-E","family":"Rodr\u00edguez-Vicente","sequence":"additional","affiliation":[{"name":"IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Department of Hematology, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2089-2742","authenticated-orcid":false,"given":"Claudia","family":"P\u00e9rez-Carretero","sequence":"additional","affiliation":[{"name":"IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Department of Hematology, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Quijada-\u00c1lamo","sequence":"additional","affiliation":[{"name":"IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Department of Hematology, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rodr\u00edguez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Department of Hematology, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-757X","authenticated-orcid":false,"given":"Jos\u00e9-\u00c1ngel","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Infanta Leonor, 28031 Madrid, Spain"},{"name":"Department of Medicine, Complutense University, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/107327481502204s02","article-title":"Chronic Lymphocytic Leukemia in the Elderly: Epidemiology and Proposed Patient-Related Approach","volume":"22","author":"Balducci","year":"2015","journal-title":"Cancer Control"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: Evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","article-title":"Geriatric assessment in older patients with a hematologic malignancy: A systematic review","volume":"105","author":"Scheepers","year":"2020","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100930","DOI":"10.1016\/j.blre.2022.100930","article-title":"CLL update 2022: A continuing evolution in care","volume":"54","author":"Kay","year":"2022","journal-title":"Blood Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_7","unstructured":"(2023, July 03). CLL\/SLL NCCN Guidelines. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s11912-022-01322-z","article-title":"How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?","volume":"24","author":"Rhodes","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdw547","article-title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: A position paper from an international Society of Geriatric Oncology (SIOG) Task Force","volume":"28","author":"Stauder","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"JCO2300933","DOI":"10.1200\/JCO.23.00933","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update","volume":"online ahead of print","author":"Dale","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e198398","DOI":"10.1001\/jamanetworkopen.2019.8398","article-title":"Global Incidence of Frailty and Prefrailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-analysis","volume":"2","author":"Chin","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/13814788.2019.1635113","article-title":"Group GIFEA Prevalence of frailty among community-dwelling elderly persons in Spain and factors associated with it","volume":"25","author":"Vrotsou","year":"2019","journal-title":"Eur. J. Gen. Pr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2021.11.009","article-title":"SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?","volume":"22","author":"Frustaci","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S2152-2650(20)30472-9","article-title":"What is Fitness in the Era of Targeted Agents?","volume":"20","author":"Tedeschi","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_15","unstructured":"(2023, April 20). SEER*Explorer Application, Available online: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=93&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&hdn_rate_type=1&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"(2016). International CLL-IPI working group An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol., 17, 779\u2013790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","article-title":"Chronic lymphocytic leukemia in the elderly: Clinico-biological features, outcomes, and proposal of a prognostic model","volume":"99","author":"Baumann","year":"2014","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1002\/cncr.25292","article-title":"Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia","volume":"116","author":"Shanafelt","year":"2010","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00277-018-3409-3","article-title":"Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia","volume":"97","author":"Strugov","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/10428194.2016.1213831","article-title":"The HOVON68 CLL trial revisited: Performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia","volume":"58","author":"Vojdeman","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00277-014-2048-6","article-title":"Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database","volume":"93","author":"Reyes","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: Results of German Chronic Lymphocytic Leukemia Study Group trials","volume":"99","author":"Goede","year":"2014","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fresa, A., Autore, F., Galli, E., Tomasso, A., Stirparo, L., Innocenti, I., and Laurenti, L. (2021). Treatment Options for Elderly\/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10215104"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2017-01-761973","article-title":"Venetoclax and obinutuzumab in chronic lymphocytic leukemia","volume":"129","author":"Fischer","year":"2017","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2147\/CMAR.S219570","article-title":"Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data","volume":"12","author":"Isaac","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Zhang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): A randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1080\/10428194.2022.2123223","article-title":"Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older","volume":"63","author":"Simon","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"885150","DOI":"10.3389\/fonc.2022.885150","article-title":"Distinct Age-Related Clinical Features and Risk Assessment in Chinese with Chronic Lymphocytic Leukemia","volume":"12","author":"Tian","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.4161\/cc.25494","article-title":"p53 mutations associated with aging-related rise in cancer incidence rates","volume":"12","author":"Richardson","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): A prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Nabhan, C., Mato, A., Flowers, C.R., Grinblatt, D.L., Lamanna, N., Weiss, M.A., Davids, M.S., Swern, A.S., Bhushan, S., and Sullivan, K. (2017). Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: Prospective evaluation on 455 patients treated in the United States. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3176-x"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.13720","article-title":"Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study","volume":"108","author":"Lund","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41375-021-01156-x","article-title":"Mapping comorbidity in chronic lymphocytic leukemia: Impact of individual comorbidities on treatment, mortality, and causes of death","volume":"35","author":"Rotbain","year":"2021","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e499","DOI":"10.1038\/bcj.2016.105","article-title":"Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: A Danish population-based study of 10455 patients","volume":"6","author":"Simonsen","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ajh.24493","article-title":"The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients","volume":"91","author":"Molica","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1080\/10428194.2016.1257791","article-title":"Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): A comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI)","volume":"58","author":"Molica","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clml.2020.03.003","article-title":"Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?","volume":"20","author":"Figueroa","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00277-018-3350-5","article-title":"Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: A systematic review and meta-analysis","volume":"97","author":"Molica","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood.V128.22.4401.4401","article-title":"Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11 Study Population","volume":"128","author":"Goede","year":"2016","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Gasc\u00f3n-y-Mar\u00edn, I., Mu\u00f1oz-Novas, C., Rodr\u00edguez-Vicente, A.-E., Quijada-\u00c1lamo, M., Hern\u00e1ndez-S\u00e1nchez, M., P\u00e9rez-Carretero, C., Ramos-Ascanio, V., and Hern\u00e1ndez-Rivas, J.-\u00c1. (2021). From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. Cancers, 13.","DOI":"10.3390\/cancers13081782"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood.2021011937","article-title":"CLL-IPI: Valid in the era of oral inhibitors?","volume":"138","author":"Kutsch","year":"2021","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","article-title":"Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia","volume":"29","author":"Wierda","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.24660","article-title":"Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI","volume":"92","author":"Delgado","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41375-020-0727-y","article-title":"Prognostic model for newly diagnosed CLL patients in Binet stage A: Results of the multicenter, prospective CLL1 trial of the German CLL study group","volume":"34","author":"Hoechstetter","year":"2020","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"105490","DOI":"10.1016\/j.compbiomed.2022.105490","article-title":"Explainable machine learning for chronic lymphocytic leukemia treatment prediction using only inexpensive tests","volume":"145","author":"Meiseles","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2022-159981","article-title":"An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment","volume":"140","author":"Cuturello","year":"2022","journal-title":"Blood"},{"key":"ref_57","unstructured":"(2023, July 03). ePrognosis\u2014About. Available online: https:\/\/eprognosis.ucsf.edu\/about.php."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11899-018-0454-x","article-title":"Frailty in Hematologic Malignancy","volume":"13","author":"Koll","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100699","DOI":"10.1016\/j.currproblcancer.2020.100699","article-title":"Integration of geriatric assessment into clinical oncology practice: A scoping review","volume":"45","author":"Okoli","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.2019001299","article-title":"Ready for prime time: Role for geriatric assessment to improve quality of care in hematology practice","volume":"134","author":"Klepin","year":"2019","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5045\/br.2022.2021218","article-title":"Assessing frailty using comprehensive geriatric assessment in older patients with hematologic malignancy","volume":"57","author":"Choi","year":"2022","journal-title":"Blood Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2021.278802","article-title":"Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies","volume":"107","author":"DuMontier","year":"2022","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2666-7568(21)00184-7","article-title":"Frailty assessment in the care of older people with haematological malignancies","volume":"2","author":"Goede","year":"2021","journal-title":"Lancet Healthy Longev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1016\/S2352-3026(21)00241-6","article-title":"A comprehensive approach to therapy of haematological malignancies in older patients","volume":"8","author":"Cordoba","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jgo.2018.09.003","article-title":"Multidisciplinary care in the hematology clinic: Implementation of geriatric oncology","volume":"10","author":"Goede","year":"2019","journal-title":"J. Geriatr. Oncol."},{"key":"ref_67","first-page":"OP2300263","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Questions and Answers","volume":"online ahead of print","author":"Williams","year":"2023","journal-title":"JCO Oncol. Pr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","article-title":"Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults with Cancer","volume":"34","author":"Hurria","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"101538","DOI":"10.1016\/j.jgo.2023.101538","article-title":"Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia","volume":"14","author":"Johnson","year":"2023","journal-title":"J. Geriatr. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.31554","article-title":"Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib","volume":"124","author":"Gordon","year":"2018","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1182\/bloodadvances.2021005716","article-title":"The CLL comorbidity index in a population-based cohort: A tool for clinical care and research","volume":"6","author":"Rotbain","year":"2022","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-3993","article-title":"The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model","volume":"27","author":"Gordon","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11912-021-01102-1","article-title":"Bruton\u2019s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation","volume":"23","author":"Sestier","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia, Gale, R.P., Chapel, H.M., Bunch, C., Rai, K.R., Foon, K., Courter, S.G., and Tait, D. (1988). Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N. Engl. J. Med., 319, 902\u2013907.","DOI":"10.1056\/NEJM198810063191403"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I manage CLL with venetoclax-based treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jgo.2015.03.003","article-title":"Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale","volume":"6","author":"Bonanad","year":"2015","journal-title":"J. Geriatr. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jgo.2016.12.008","article-title":"Further psychometric validation of the GAH scale: Responsiveness and effect size","volume":"8","author":"Soler","year":"2017","journal-title":"J. Geriatr. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"101401","DOI":"10.1016\/j.jgo.2022.10.016","article-title":"Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study","volume":"14","author":"Iglesias","year":"2023","journal-title":"J. Geriatr. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1200\/JCO.21.00118","article-title":"Models of Care in Geriatric Oncology","volume":"39","author":"Chapman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/ageing\/afaa257","article-title":"Adaptation of the comprehensive geriatric assessment to a virtual delivery format","volume":"50","author":"Loewenthal","year":"2020","journal-title":"Age Ageing"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JOP.2017.026435","article-title":"What Every Oncologist Should Know About Geriatric Assessment for Older Patients with Cancer: Young International Society of Geriatric Oncology Position Paper","volume":"14","author":"Loh","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"775050","DOI":"10.3389\/fonc.2021.775050","article-title":"Integration of a Geriatric Assessment with Intervention in the Care of Older Adults with Hematologic Malignancies","volume":"11","author":"Wall","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/ejh.13570","article-title":"Impact of a comprehensive geriatric assessment on decision-making in older patients with hematological malignancies","volume":"106","author":"Garric","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"12011","DOI":"10.1200\/JCO.2020.38.15_suppl.12011","article-title":"Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy","volume":"38","author":"Soo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2015.1091933","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group","volume":"57","author":"Goede","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/10428194.2018.1508674","article-title":"A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients","volume":"60","author":"Molica","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Van Der Straten, L., Stege, C.A.M., Kersting, S., Nasserinejad, K., Dubois, J., Dobber, J.A., Mellink, C.H.M., van der Kevie-Kersemaekers, A.-M.F., Evers, L.M., and de Boer, F. (2023). Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit CLL patients. Blood, online ahead of print, blood.2023020195.","DOI":"10.1182\/blood.2023020195"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2021-153146","article-title":"Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.1002\/ajh.24773","article-title":"Real-world results of ibrutinib in relapsed\/refractory CLL in France: Early results on a large series of 428 patients","volume":"92","author":"Ysebaert","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_105","unstructured":"(2023, July 26). Chronische Lymphatische Leuk\u00e4mie (CLL). Available online: https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/chronische-lymphatische-leukaemie-cll."},{"key":"ref_106","unstructured":"(2023, July 28). Gu\u00eda de Tratamiento de la LLC. Available online: https:\/\/www.gellc.es\/noticias\/110-guia-de-tratamiento-de-la-llc."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Zuccarino, S., Monacelli, F., Antognoli, R., Nencioni, A., Monzani, F., Ferr\u00e8, F., Seghieri, C., and Antonelli Incalzi, R. (2022). Exploring Cost-Effectiveness of the Comprehensive Geriatric Assessment in Geriatric Oncology: A Narrative Review. Cancers, 14.","DOI":"10.3390\/cancers14133235"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4391\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:45:19Z","timestamp":1760129119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":107,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cancers15174391"],"URL":"https:\/\/doi.org\/10.3390\/cancers15174391","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,2]]}}}